Bildkälla: Stockfoto

Herantis Pharma: Announces positive phase Ia data - Redeye

Redeye is positive towards the top-line data from the phase Ia trial with HER-096 presented by Herantis. We raise our base case and look forward to an exciting 2024.

Redeye is positive towards the top-line data from the phase Ia trial with HER-096 presented by Herantis. We raise our base case and look forward to an exciting 2024.
Börsvärldens nyhetsbrev
ANNONSER